Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard
Business Of Biotech
00:00
The Role of Microbiome Therapeutics in Cancer
I never thought about a global approach to clinical trials with multiple agencies as being like strategic from a redundancy perspective before. But I mean, all of us, US, Europe, everywhere, we want to bring innovations to patients and we might have different concerns. So that's maybe why I thought in a different manner. Yeah. And if you can validate some milestones with the different agencies, I know another microbiome company, for example, has been a start in France for certain reasons. I know they have started in Belgium. They have provided provided human data, not nonclinical data. And from that the French agency, they say, that's okay, you check the box. That was very important
Transcript
Play full episode
